Hillsdale Investment Management Inc. Acquires New Holdings in LifeMD, Inc. $LFMD

Hillsdale Investment Management Inc. bought a new stake in LifeMD, Inc. (NASDAQ:LFMD) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 26,800 shares of the company’s stock, valued at approximately $365,000. Hillsdale Investment Management Inc. owned approximately 0.06% of LifeMD as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in LFMD. CWM LLC grew its holdings in shares of LifeMD by 17.5% in the 1st quarter. CWM LLC now owns 9,050 shares of the company’s stock valued at $49,000 after buying an additional 1,351 shares during the period. Nisa Investment Advisors LLC lifted its holdings in LifeMD by 148.5% during the second quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company’s stock worth $50,000 after acquiring an additional 2,185 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in shares of LifeMD by 1,004.9% in the second quarter. Caitong International Asset Management Co. Ltd now owns 5,171 shares of the company’s stock worth $70,000 after acquiring an additional 4,703 shares in the last quarter. Ieq Capital LLC bought a new stake in shares of LifeMD in the first quarter worth about $114,000. Finally, Baader Bank Aktiengesellschaft acquired a new stake in shares of LifeMD during the second quarter worth about $136,000. 35.52% of the stock is owned by institutional investors.

Insider Activity

In related news, insider Nicholas P. Alvarez sold 75,000 shares of the company’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $5.92, for a total transaction of $444,000.00. Following the sale, the insider owned 605,000 shares in the company, valued at approximately $3,581,600. This represents a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 18.40% of the company’s stock.

Analyst Ratings Changes

LFMD has been the subject of several research analyst reports. B. Riley decreased their price objective on LifeMD from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Zacks Research cut shares of LifeMD from a “hold” rating to a “strong sell” rating in a report on Thursday. BTIG Research lowered their price objective on shares of LifeMD from $18.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Wall Street Zen lowered shares of LifeMD from a “hold” rating to a “sell” rating in a report on Saturday. Finally, HC Wainwright reduced their target price on shares of LifeMD from $13.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, November 19th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $9.43.

LifeMD Stock Up 3.8%

Shares of LFMD stock opened at $3.85 on Monday. LifeMD, Inc. has a 12 month low of $3.43 and a 12 month high of $15.84. The company’s fifty day simple moving average is $5.88 and its 200-day simple moving average is $8.60. The firm has a market cap of $185.34 million, a PE ratio of -22.65 and a beta of 1.57.

LifeMD (NASDAQ:LFMD) last released its earnings results on Monday, November 17th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The company had revenue of $60.17 million for the quarter, compared to analyst estimates of $62.07 million. During the same period in the prior year, the business posted $0.09 earnings per share. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities analysts predict that LifeMD, Inc. will post -0.56 earnings per share for the current fiscal year.

LifeMD Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.